Related Experiment Video

Updated: Mar 20, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

2.0K

Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae

P Gagetti1, F Pasteran2, M P Martinez3

  • 1Houston Methodist Research Institute, Houston, Texas, USA Servicio Antimicrobianos, INEI-ANLIS Dr Carlos Malbrán, Buenos Aires, Argentina.

Antimicrobial Agents and Chemotherapy
|May 25, 2016
PubMed

Insights

The daptomycin-meropenem combination shows promise for treating infections caused by KPC-producing Klebsiella pneumoniae. This novel strategy may offer a new therapeutic option against these difficult-to-treat Gram-negative bacteria.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Klebsiella pneumoniae carbapenemase (KPC)-producing strains cause severe infections in vulnerable patients.
  • These infections are linked to extended hospital stays and higher mortality rates.
  • Daptomycin is typically used for Staphylococcus aureus and considered ineffective against Gram-negative bacteria.

Purpose of the Study:

  • To investigate the effectiveness of a daptomycin-meropenem combination against KPC-producing Klebsiella pneumoniae.
  • To explore a potential novel therapeutic strategy for challenging Gram-negative infections.

Main Methods:

  • Synergy kill curve analysis was employed.
  • Pharmacokinetic/pharmacodynamic (PK/PD) modeling was utilized.

Main Results:

  • The daptomycin-meropenem combination demonstrated effectiveness.
  • The study provides evidence supporting the combination's potential.

Conclusions:

  • The daptomycin-meropenem combination may represent a novel therapeutic strategy.
  • Further research is warranted to validate its clinical utility against KPC-producing Klebsiella pneumoniae infections.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.3K
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

1.2K

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
62
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
73
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
1.4K
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
7
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
717